As of November 8, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Valion Bio, Inc. The largest reported stake is Murchinson Ltd.'s, at 9.99%. 12 filings are on record since February 27, 2026 (Schedule 13G, July 17, 2026).
Sell to companies like Valion Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: 3i, LP · Percent: 9.9% · Shares: 132,671 · SCHEDULE 13G/A
- · Holder: 3i, LP · Percent: 9.9% · SCHEDULE 13D/A
- · Holder: 3i, LP · Percent: 9.9% · SCHEDULE 13D/A
- · Holder: 3i, LP · Percent: 9.9% · SCHEDULE 13D/A
- · Holder: 3i, LP · Percent: 9.9% · SCHEDULE 13D/A
Valion Bio, Inc. has 12 Schedule 13D or 13G filings on record since 2026-02-27. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2025-11-14 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Murchinson Ltd. | 9.99% | 440,242 | SCHEDULE 13G, 2026-07-17 | 2026-06-08 |
| 3i, LP | 9.9% | 132,671 | SCHEDULE 13G/A, 2026-09-04 | 2026-09-04 |
Holding shares or following this stake? See who's behind Valion Bio, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Valion Bio, Inc. and the records around it.
Valion Bio, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Company profile and every filing Dec 2025
- Form D filing Dec 2025
- Form D filing Dec 2025
- Layoff notices Nov 2025
- Who owns it
Companies that share a holder
- Murchinson Ltd. also filed stake reports on 2 other companies: Nano Dimension Ltd. (Oct 2026), Pelthos Therapeutics Inc. (Nov 2025)
- 3i, LP also filed stake reports on 11 other companies: Netcapital Inc. (May 2026), Pelthos Therapeutics Inc. (May 2026), zSpace, Inc. (Apr 2026)
Watch Valion Bio, Inc.
Get an email when Valion Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Valion Bio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Valion Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Valion Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Murchinson Ltd. | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| Marc Bistricer | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| BPY Ltd. | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| Nomis Bay Ltd. | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| Nomis Bay Opportunity Ltd. | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| EOM Management Ltd. | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| James Keyes | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| Jason Jagessar | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| Chaja Carlebach | 0 | 440,242 | 0 | 440,242 | SCHEDULE 13G, 2026-07-17 |
| 3i, LP | 0 | 132,671 | 0 | 132,671 | SCHEDULE 13G/A, 2026-09-04 |
| Tumim Stone Capital, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-09-04 |
| 3i Management LLC | 0 | 132,671 | 0 | 132,671 | SCHEDULE 13G/A, 2026-09-04 |
| Maier J. Tarlow | 0 | 132,671 | 0 | 132,671 | SCHEDULE 13G/A, 2026-09-04 |
The latest filing identifies Valion Bio, Inc. by CUSIP 918942202 and gives its principal executive office as 1305 E. Houston Street, Building 1, Suite 311, San Antonio, TX 78205 (SCHEDULE 13G/A, 2026-09-04).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-27 | 3i, LP | 9.9% | SCHEDULE 13G |
| 2026-05-08 | 3i, LP | 9.9% | SCHEDULE 13G/A |
| 2026-07-17 | Murchinson Ltd. | 9.99% | SCHEDULE 13G |
| 2026-08-03 | 3i, LP | 9.9% | SCHEDULE 13D |
| 2026-08-11 | 3i, LP | 9.9% | SCHEDULE 13D/A |
| 2026-08-14 | 3i, LP | 9.9% | SCHEDULE 13D/A |
| 2026-08-19 | 3i, LP | 9.9% | SCHEDULE 13D/A |
| 2026-08-24 | 3i, LP | 9.9% | SCHEDULE 13D/A |
| 2026-08-27 | 3i, LP | 9.9% | SCHEDULE 13D/A |
| 2026-09-02 | 3i, LP | 9.9% | SCHEDULE 13D/A |
| 2026-09-03 | 3i, LP | 9.9% | SCHEDULE 13D/A |
| 2026-09-04 | 3i, LP | 9.9% | SCHEDULE 13G/A |
Questions about who owns Valion Bio, Inc.
Who owns Valion Bio, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Valion Bio, Inc.: Murchinson Ltd. (9.99%, Schedule 13G, filed 2026-07-17) and 3i, LP (9.9%, Schedule 13G/A, filed 2026-09-04).
Who are the largest shareholders of Valion Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of Valion Bio, Inc. on this page are Murchinson Ltd. (9.99%) and 3i, LP (9.9%).
When did Murchinson Ltd. buy into Valion Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Murchinson Ltd. on this page is the Schedule 13G, filed 2026-07-17, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Valion Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Leadership change: Lisa Wolf departs, Chief Operating Officer and Chief Financial Officer | — | Leadership changes | Source |
| November 2, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 23, 2026 | Leadership change: Dean Zikria appointed, Chief Executive Officer, and 1 more | — | Leadership changes | Source |
| September 1, 2026 | Leadership change: Jared Malbin appointed, Director, and 1 more | — | Leadership changes | Source |
| August 17, 2026 | Leadership change: Lisa Wolf appointed, Chief Operating Officer | — | Leadership changes | Source |
| May 4, 2026 | Leadership change: Melinda Lackey appointed, General Counsel | — | Leadership changes | Source |
| December 29, 2025 | Form D, private offering | $12M sold | Form D page | Source |
| December 29, 2025 | Form D, private offering | $16.25M sold | Form D page | Source |
Valion Bio, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Valion Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.